Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Genduso

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The American Journal of Managed Care|May 7, 1997
Cost of illness studies for schizophrenia: components, benefits, results, and implicationsL A Genduso, J C Haley
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 31, 1997
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trialS H Hamilton, D A Revicki, L A Genduso, et al.
Pharmacoeconomics|October 28, 1999
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trialS H Hamilton, D A Revicki, E T Edgell, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 4, 1999
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trialD A Revicki, L A Genduso, S H Hamilton, et al.
The American Journal of Managed Care|February 6, 1998
A cost-effectiveness clinical decision analysis model for schizophreniaC S Palmer, D A Revicki, L A Genduso, et al.
Journal of Affective Disorders|January 11, 1992
Fluoxetine: no association with suicidality in obsessive-compulsive disorderC M Beasley, J H Potvin, D N Masica, et al.
Archives of General Psychiatry|July 1, 1994
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorderG D Tollefson, A H Rampey, J H Potvin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The American Journal of Managed Care|May 7, 1997
Cost of illness studies for schizophrenia: components, benefits, results, and implicationsL A Genduso, J C Haley
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 31, 1997
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trialS H Hamilton, D A Revicki, L A Genduso, et al.
Pharmacoeconomics|October 28, 1999
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trialS H Hamilton, D A Revicki, E T Edgell, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 4, 1999
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trialD A Revicki, L A Genduso, S H Hamilton, et al.
The American Journal of Managed Care|February 6, 1998
A cost-effectiveness clinical decision analysis model for schizophreniaC S Palmer, D A Revicki, L A Genduso, et al.
Journal of Affective Disorders|January 11, 1992
Fluoxetine: no association with suicidality in obsessive-compulsive disorderC M Beasley, J H Potvin, D N Masica, et al.
Archives of General Psychiatry|July 1, 1994
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorderG D Tollefson, A H Rampey, J H Potvin, et al.
Pageof 1